Johnson & Johnson's Q2 Earnings Call Highlights Pharma Strength and MedTech Concerns
Johnson & Johnson (J&J) raised its full-year revenue guidance due to strong performance in its pharmaceutical division, particularly from the immunology drug TREMFYA. However, concerns were raised during the earnings call about a slowdown in its MedTech segment, especially within Abiomed's heart pump business.
Tickers: $JNJ
Topics: guidance medtech pharmaceuticals revenue growth